Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-07-01
2008-07-01
Helms, Larry (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387300, C536S023530
Reexamination Certificate
active
10453698
ABSTRACT:
Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
REFERENCES:
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5908925 (1999-06-01), Cohen et al.
patent: 6254868 (2001-07-01), Leung et al.
patent: 2002/0177170 (2002-11-01), Luo et al.
patent: 2003/0040606 (2003-02-01), Leung
patent: 2003/0109680 (2003-06-01), Wong et al.
patent: 2003/0190705 (2003-10-01), Wong et al.
patent: 0939127 (1999-09-01), None
patent: WO03/002607 (2003-01-01), None
patent: WO03/025019 (2003-03-01), None
Rudikoff et al (Proc. Natl. Acad. Sci. USA 79:1979 (1982).
Rosok et al. J. Biol. Biochem. 271:22611-22618 (1996).
Harris et al., Prot. Sci. 4:306-310 (1995)
“Humanization of Immu31, an α-Fetoprotein-specific Antibody”, Qu et al.,Clinical Cancer Reasearch, The American Association For Cancer Research, US, vol. 5, No. 10, pp.3095S-3100S (1999).
“Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific, Leukemia/Lymphoma Antibody, LL2”, Leung et al.,Molecular Immunology, vol. 31, pp. 17-18 (1995).
Takeda S.,Nature, Apr. 4-10, 1985; 314 (6010):452-4, “Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequence”.
Jones PT.,Nature, May 29-June 4, 1986; 321 (6069); 522-5, “Replacing the Complementaryity-Determining Regions in a Human Antibody With Those From a Mouse”.
Sato K.,Immunol., Apr. 1995; 31 (5):371-81, “Humanization of a Mouse Anti-Human Interleukin-6 Receptor Antibody Comparing Two Methods For Selecting Human Framework Regions”.
Chothia C.;J. Moi Biol., Aug. 1987; 196 (4): 901-17, “Canonical Structures For the Hypervariable Regions of Immunoglobulins”.
Foote J.,J. Moi Biol., Mar. 20, 1992; 224 (2) 487-99, “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”.
Santos AD.,Prog. Nucleic Acid Res. Moi Biol. 1998; 60:164-94, “Development of More Efficacious Antibody for Medical Therapy and Diagnosis”.
Rosok MJ,J. Biol. Chem.lSep. 13, 1996; 271 (37): 2211-8, “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab.”
Reichmann L. et al.,Nature1988, 332, 323-327, “Reshaping Human Antibodies for Therapy”.
Yelton et al.,The Journal of Immunology1995, pp. 1994-2004, “Affinity Maturation of the BR96 Anti-Carcinoma Antibody By Condo Based Mutagenesis”.
vol. 272, No. 16, Issue of Apr. 18, 1997, pp. 10678-10684, “Antibody Humanization Using Momovalent Phage Display”.
Baca, M. et al., “Antibody Humanization Using Monovalent Phage Display,”J. Biol. Chem. 272(16): 10678-10684, (1997).
Benhar, I. et al., “Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38,”Proc. Natl. Acad. Sci. USA 91: 12051-12055, (Dec. 1994).
Couto, J. et al., “Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus andin Vivoandin VitroCharacterization,”Cancer Res. 55:1717-1722, (Apr. 15, 1995).
Leung, S-O, et al., “Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific Leukemia/Lymphoma Antibody, LL2,”Mol. Immunol. 32(17/18): 1413-1427, (1995).
Radar, C. et al. “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,”Proc. Natl. Acad. Sci. USA 95: 8910-8915, (Jul. 1998).
Ohtomo, T. et al. “Humanization of Mouse ONS-M21 Antibody with the aid of hybrid variable regions,”Mol. Immunol. 32(6): 407-416, (1995).
Rosok et al., “A Combinatorial Library Stategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” Journal of Biological Chemistry, 271(37):22611-22618, (1996).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79:1979-1983, (1982).
Rother Russell
Wu Dayang
Alexion Pharmaceuticals, Inc.
Bristol Lynn
Helms Larry
Ropes & Gray LLP
LandOfFree
Hybrid antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3927643